Individualized dosing with axitinib: rationale and practical guidance

Schmidinger, M., Danesi, R., Jones, R. , McDermott, R., Pyle, L., Rini, B. and Négrier, S. (2018) Individualized dosing with axitinib: rationale and practical guidance. Future Oncology, 14(9), pp. 861-875. (doi: 10.2217/fon-2017-0455) (PMID:29264944)

154433.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.



Axitinib is a potent, selective, vascular endothelial growth factor receptor inhibitor with demonstrated efficacy as second-line treatment for metastatic renal cell carcinoma. Analyses of axitinib drug exposures have demonstrated high interpatient variability in patients receiving the 5 mg twice-daily (b.i.d.) starting dose. Clinical criteria can be used to assess whether individual patients may benefit further from dose modifications, based on their safety and tolerability data. This review provides practical guidance on the ‘flexible dosing’ method, to help physicians identify who would benefit from dose escalations, dose reductions or continuation with manageable toxicity at the 5 mg b.i.d. dose. This flexible approach allows patients to achieve the best possible outcomes without compromising safety.

Item Type:Articles
Additional Information:This review was sponsored by Pfizer Pharma GmbH.
Glasgow Author(s) Enlighten ID:Jones, Professor Robert
Authors: Schmidinger, M., Danesi, R., Jones, R., McDermott, R., Pyle, L., Rini, B., and Négrier, S.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Future Oncology
Publisher:Future Medicine
ISSN (Online):1744-8301
Published Online:21 December 2017
Copyright Holders:Copyright © 2017 Manuela Schmidinger
First Published:First published in Future Oncology 14(9):861-875
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record